UNSPSC 51273948: Sodium chloride/thiopental

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN202. This VA Drug Class (CN202) classifies this compound as belonging to the group BARBITURIC ACID DERIVATIVE ANESTHETICS.

UNSPSC 51273948 Sodium chloride/thiopental is a Commodity code that nominally covers pharmaceutical compounds used in medical and veterinary contexts, but recent state and local solicitations under this code show minimal direct relevance to the code's scope. State and local governments are procuring naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs through competitive bidding and cooperative purchasing vehicles, yet none of these acquisitions map cleanly to sodium chloride/thiopental specifically. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The procurement mechanisms span IFBs for immediate supply needs, RFIs for market intelligence and program design, and RFPs for multi-year supplier agreements. Vendors responding to these opportunities must meet federal and state compliance standards including Good Manufacturing Practices, Drug Supply Chain Security Act certification, E-Verify requirements, and FDA registration, alongside standard insurance and drug-free workplace certifications.

Recent activity clusters in Florida and Minnesota, with broader multi-state reach through cooperative purchasing. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries by July 26, 2023 (note: deadline date appears inconsistent with posting date). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs serving state and self-insured employer plans. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) posted January 20, 2026, with a March 26, 2026 response deadline, establishing multi-year contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota, Oregon, and participating jurisdictions through three authorized wholesalers. The code shows limited activity specifically targeting sodium chloride/thiopental and warrants verification against actual commodity sourcing practices in target jurisdictions.